May 15, 2020 / 12:30 PM / 21 days ago

BRIEF-Blueprint Medicines Receives Complete Response Letter From FDA For Avapritinib NDA For The Treatment Of Fourth-Line Gastrointestinal Stromal Tumor

May 15 (Reuters) - Blueprint Medicines Corp:

* BLUEPRINT MEDICINES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR AVAPRITINIB NEW DRUG APPLICATION FOR THE TREATMENT OF FOURTH-LINE GASTROINTESTINAL STROMAL TUMOR

* BLUEPRINT MEDICINES CORP - CRL STATES THAT FDA CANNOT APPROVE APPLICATION.

* BLUEPRINT MEDICINES CORP - CONTINUES TO ADVANCE DEVELOPMENT OF AVAPRITINIB FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below